1 completed, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow GSK598809: new trials by email Literature Review of GSK598809 trials Research Report on GSK598809
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention GSK598809, Placebo - Nicotine Dependence | Phase 2 | Completed | Massachusetts General Hospital | 84 | 2010-08-01 | 2017-02-23 |
| Relapse Prevention Study in Newly Abstinent Smokers GSK598809, Nicotine Replacement Transdermal Patch, Placebo - Substance Dependence | Phase 2 | Withdrawn | GlaxoSmithKline | 2008-12-01 | 2016-02-15 |
Tobacco Use Disorder (2) · Smoking (1) · Smoking Cessation (1) · Substance-Related Disorders (1)
GlaxoSmithKline (1) · Massachusetts General Hospital (1)
United States (2)
Eden Evins, MD, MPH (1) · Maurizio Fava, MD (1)
U01DA019378 (1)